Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

Open access

Abstract

BACKGROUND: Type 2 diabetes (T2D) is associated with generalized vascular dysfunction characterized by increases in large artery stiffness, endothelial dysfunction, and vascular smooth muscle dysfunction. Sodium glucose cotransporter 2 inhibitors (SGLT2i) represent the most recently approved class of oral medications for the treatment of T2D, and have been shown to reduce cardiovascular and overall mortality. Although it is currently unclear how SGLT2i decrease cardiovascular risk, an improvement in vascular function is one potential mechanism. The aim of the current study was to examine if dapagliflozin, a widely prescribed STLT2i, improves generalized vascular dysfunction in type 2 diabetic mice. In light of several studies demonstrating a bi-directional relation between orally ingested medications and the gut microbiota, a secondary aim was to determine the effects of dapagliflozin on the gut microbiota. METHODS: Male diabetic mice (Db, n = 24) and control littermates (Con; n = 23) were randomized to receive either a standard diet or a standard diet containing dapagliflozin (60 mg dapagliflozin/kg diet; 0.006%) for 8 weeks. Arterial stiffness was assessed by aortic pulse wave velocity; endothelial function and vascular smooth muscle dysfunction were assessed by dilatory responses to acetylcholine and sodium nitroprusside, respectively. RESULTS: Compared to untreated diabetic mice, diabetic mice treated with dapagliflozin displayed significantly lower arterial stiffness (Db = 469 cm/s vs. Db + dapa = 435 cm/s, p < 0.05), and improvements in endothelial dysfunction (area under the curve [AUC] Db = 57.2 vs. Db + dapa = 117.0, p < 0.05) and vascular smooth muscle dysfunction (AUC, Db = 201.7 vs. Db + dapa = 285.5, p < 0.05). These vascular improvements were accompanied by reductions in hyperglycemia and circulating markers of inflammation. The microbiota of Db and Con mice were distinctly different, and dapagliflozin treatment was associated with minor alterations in gut microbiota composition, particularly in Db mice, although these effects did not conclusively mediate the improvements in vascular function. CONCLUSIONS: Dapagliflozin treatment improves arterial stiffness, endothelial dysfunction and vascular smooth muscle dysfunction, and subtly alters microbiota composition in type 2 diabetic mice. Collectively, the improvements in generalized vascular function may represent an important mechanism underlying the cardiovascular benefits of SGLT2i treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-018-0708-x

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The effects of dapagliflozin on body weight and fasting (6 h) blood glucose. a Changes in body weight from weeks 0 to 8; b 6 h fasted blood glucose levels from 0 to 8 weeks. Data are expressed as mean ± SEM; *p < 0.05 vs all other groups at the same time point; +p<0.05 vs both Con groups at same time point; #p < 0.05 from week 0 within the same treatment group; n = 11–12/group
Fig. 1 The effects of dapagliflozin on body weight and fasting (6 h) blood glucose. a Changes in body weight from weeks 0 to 8; b 6 h fasted blood glucose levels from 0 to 8 weeks. Data are expressed as mean ± SEM; *p < 0.05 vs all other groups at the same time point; +p<0.05 vs both Con groups at same time point; #p < 0.05 from week 0 within the same treatment group; n = 11–12/groupCC BY · PubMed Central
Fig. 2 The effects of dapagliflozin on endothelium dependent- and -independent dilation. a Endothelium-dependent dilation; b area under of the curve for endothelium-dependent dilation (EDD); c endothelium-independent dilation; d area under of the curve for endothelium-independent dilation (EID). Data are expressed as mean ± SEM; *p < 0.05 vs, all other groups; #p < 0.05 vs both Db groups; $p < 0.05 vs Db group; n = 10–12/group
Fig. 2 The effects of dapagliflozin on endothelium dependent- and -independent dilation. a Endothelium-dependent dilation; b area under of the curve for endothelium-dependent dilation (EDD); c endothelium-independent dilation; d area under of the curve for endothelium-independent dilation (EID). Data are expressed as mean ± SEM; *p < 0.05 vs, all other groups; #p < 0.05 vs both Db groups; $p < 0.05 vs Db group; n = 10–12/groupCC BY · PubMed Central
Fig. 3 The effects of dapagliflozin on aortic pulse wave velocity (aPWV). aPWV after 8 weeks of dapagliflozin treatment. Data are expressed as mean ± SEM; *p < 0.05 vs all other groups; n = 10–12/group
Fig. 3 The effects of dapagliflozin on aortic pulse wave velocity (aPWV). aPWV after 8 weeks of dapagliflozin treatment. Data are expressed as mean ± SEM; *p < 0.05 vs all other groups; n = 10–12/groupCC BY · PubMed Central
Fig. 4 The effects of dapagliflozin on circulating markers of inflammation. a Monocyte chemoattractant protein-1 (MCP-1); b interleukin-1 beta (IL-1β); c interleukin-6 (IL-6); d interleukin-17 (IL-17); e interleukin-10 (IL-10); f chemokine ligand 5 (CCL5). Data are expressed as mean ± SEM; *p < 0.05 vs all other groups; $p < 0.05 vs Con and Db + dapa; n = 3–8/group. ND below detectable limits
Fig. 4 The effects of dapagliflozin on circulating markers of inflammation. a Monocyte chemoattractant protein-1 (MCP-1); b interleukin-1 beta (IL-1β); c interleukin-6 (IL-6); d interleukin-17 (IL-17); e interleukin-10 (IL-10); f chemokine ligand 5 (CCL5). Data are expressed as mean ± SEM; *p < 0.05 vs all other groups; $p < 0.05 vs Con and Db + dapa; n = 3–8/group. ND below detectable limitsCC BY · PubMed Central
Fig. 5 Microbiota characteristics of beta- and alpha-diversity after 8 weeks of treatment with dapagliflozin. a PCoA of OTU-level Bray–Curtis; b hierarchical clustering of OTU-level Bray–Curtis distances using Ward’s linkage; c Chao1 richness estimates; and d Shannon diversity measure of fecal samples across treatment groups OTU. Box represents 25th–75th percentiles, median values are represented by boxplot internal line and ranges by whiskers; #p < 0.05 vs both Con groups; n = 6–10/group
Fig. 5 Microbiota characteristics of beta- and alpha-diversity after 8 weeks of treatment with dapagliflozin. a PCoA of OTU-level Bray–Curtis; b hierarchical clustering of OTU-level Bray–Curtis distances using Ward’s linkage; c Chao1 richness estimates; and d Shannon diversity measure of fecal samples across treatment groups OTU. Box represents 25th–75th percentiles, median values are represented by boxplot internal line and ranges by whiskers; #p < 0.05 vs both Con groups; n = 6–10/groupCC BY · PubMed Central
Fig. 6 Phyla level characteristics of the microbiota. Relative abundance of a Actinobateria; b Proteobateria; c Bateriodetes; d Firmicutes; e Verrucomicrobioa; f Firmicutes:Bacteriodetes ratio. Box represents 25th–75th percentiles, median values are represented by boxplot internal line and ranges by whiskers; *p < 0.05 vs all other groups, #p < 0.05 vs Con groups, $p < 0.05 vs Con; n = 6–10/group
Fig. 6 Phyla level characteristics of the microbiota. Relative abundance of a Actinobateria; b Proteobateria; c Bateriodetes; d Firmicutes; e Verrucomicrobioa; f Firmicutes:Bacteriodetes ratio. Box represents 25th–75th percentiles, median values are represented by boxplot internal line and ranges by whiskers; *p < 0.05 vs all other groups, #p < 0.05 vs Con groups, $p < 0.05 vs Con; n = 6–10/groupCC BY · PubMed Central
Fig. 7 Species level characteristics of the microbiota. Abundance of a Akkermansia; b Oscillispira; c Enterococcus; d Lactobacillus. Box represents 25th–75th percentiles, median values are represented by boxplot internal line and ranges by whiskers; ^p < 0.05 vs Con; *p < 0.05 vs all other groups, #p < 0.05 vs both Con groups; n = 6–10/group
Fig. 7 Species level characteristics of the microbiota. Abundance of a Akkermansia; b Oscillispira; c Enterococcus; d Lactobacillus. Box represents 25th–75th percentiles, median values are represented by boxplot internal line and ranges by whiskers; ^p < 0.05 vs Con; *p < 0.05 vs all other groups, #p < 0.05 vs both Con groups; n = 6–10/groupCC BY · PubMed Central
Fig. 8 Correlations between microbiota and vascular outcomes. a aPWV and Akkermansia abundance; b EDD AUC and Akkermansia abundance; c EID AUC and Akkermansia abundance; d EDD AUC and Proteobacteria relative abundance; e aPWV and Firmicutes relative abundance; f aPWV and F:B ratio. r and p values are given following Pearson’s correlation test. n = 6–10/group
Fig. 8 Correlations between microbiota and vascular outcomes. a aPWV and Akkermansia abundance; b EDD AUC and Akkermansia abundance; c EID AUC and Akkermansia abundance; d EDD AUC and Proteobacteria relative abundance; e aPWV and Firmicutes relative abundance; f aPWV and F:B ratio. r and p values are given following Pearson’s correlation test. n = 6–10/groupCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 247

Metadata

Authors
Lee, D. M., Battson, M. L., Jarrell, D. K., Hou, S., Ecton, K. E., Weir, T. L., & Gentile, C. L.
Affiliations
Colorado State University (US)
Corresponding author
Gentile, Christopher L.
Venue
Cardiovascular Diabetology
Published
2018-04-27
Volume
17
Issue
1
Pages
62-62
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2807501871
Cited by
246
References
58
Citations by year
2026: 15 · 2025: 19 · 2024: 33 · 2023: 46 · 2022: 52 · 2021: 26 · 2020: 27 · 2019: 22 · 2018: 6
FWCI
16.10
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
dapagliflozin, SGLT2 inhibitors, type 2 diabetes, vascular dysfunction, arterial stiffness, endothelial dysfunction, vascular smooth muscle dysfunction, gut microbiota, pulse wave velocity, acetylcholine response, sodium nitroprusside response, hyperglycemia, inflammation, diabetic mice, cardiovascular risk reduction, drug-microbiota interactions
MeSH terms
Gastrointestinal Microbiome, Sodium-Glucose Transporter 2 Inhibitors, Animals, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Glucosides, Intestines, Male, Muscle, Smooth, Vascular, Vasodilation, Sodium-Glucose Transporter 2, Mice, Vascular Stiffness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. https://app.cochat.ai/papers/10.1186/s12933-018-0708-x
The paper
Lee, D. M., Battson, M. L., Jarrell, D. K., Hou, S., Ecton, K. E., Weir, T. L., & Gentile, C. L. (2018). SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-018-0708-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.